OncoTRACE is a test based on circulating tumor DNA (ctDNA) in liquid biopsies (principally blood). It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears. This assay is customized for each patient, as it contains personal cancer-specific markers and variants identified in a previous genomic analysis.
In 2013 OncoDNA became the first company to personalize a specific OncoTRACE test for every patient (a recent publication in 2017 in Nature demonstrates the efficacy of such an approach).
The test is customized for each patient, by first selecting a set of patient-specific variants, identified in the tumor by a previous genetic test (like our OncoSTRAT&GO solution or tests like FoundationOne® from Foundation Medicine, CGP+ from Caris Molecular Intelligence or Guardant360 from Guardant Health). The first set of markers is associated with a second panel of specific variants, often related to resistance or sensitivity to targeted therapies, then with a third set of markers found frequently in the early development of the tumor. 3 levels of personalization, one powerful monitoring tool.
A personalized, unique panel is manufactured for each patient. The panel can then be used repeatedly on any liquid biopsy sample (usually blood). For the first time this minimally invasive technique enables, the oncologist to follow the treatment response very closely, detect relapse earlier than routine imaging technologies and identify new targets if the cancer grows resistant to the current therapy.
Just send us a blood sample (2 Streck tubes each containing 10 ml).
How much does OncoTRACE cost?
Please inquire for country specific price information for this solution, please send an email at this address: email@example.com
Our tests are currently reimbursed in a growing number of countries. In the United Kingdom, OncoSTRAT&GO is reimbursed for patients insured by BUPA Global Insurance, using code 7331B. Other countries, like Spain, Chili, South Africa and Poland, also cover the cost of our tests, either totally or partially. Don’t hesitate to contact us for more information.
Alicia, 49 years old when diagnosed
Was given the OncoDEEP solution following a stage 3 lung cancer.